Sitagliptin With Semaglutide
Concomitant use of a DPP-4 inhibitor (sitagliptin/Januvia) with a GLP-1 receptor agonist (semaglutide/Ozempic) is not recommended because no added clinical benefit is provided. [1]
When a GLP-1 receptor agonist is used, the DPP-4 inhibitor should be discontinued when possible. [1]
Medication Selection Algorithm
- GLP-1 receptor agonist therapy (semaglutide/Ozempic) is selected for incretin-based glucose lowering. [1]
- DPP-4 inhibitor therapy (sitagliptin/Januvia) should be avoided in combination with GLP-1 receptor agonist therapy. [1]
Monotherapy vs Combination Therapy
- Combination therapy with GLP-1 receptor agonists and DPP-4 inhibitors is not recommended due to lack of additional benefit over GLP-1 receptor agonist therapy alone. [1]
Important Clarifications or Nuances
- Discontinuation of the DPP-4 inhibitor does not require tapering. [1]
Initiation Thresholds or Indications
- DPP-4 inhibitor continuation is not indicated when semaglutide is being used for type 2 diabetes management. [1]
Common Pitfalls to Avoid
- Continuing sitagliptin (Januvia) after starting semaglutide (Ozempic) increases polypharmacy without added efficacy. [1]
Targets or Goals of Therapy
- Glycemic control should be achieved using the GLP-1 receptor agonist regimen rather than maintaining dual incretin therapy with sitagliptin. [1]